{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:30:28Z","timestamp":1772641828127,"version":"3.50.1"},"reference-count":18,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1111\/jcpt.12273","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T23:34:32Z","timestamp":1428708872000},"page":"391-397","source":"Crossref","is-referenced-by-count":3,"title":["A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10\u00a0years"],"prefix":"10.1155","volume":"40","author":[{"given":"A.-S.","family":"Lang","sequence":"first","affiliation":[{"name":"Pharmacy Department; University Hospital; Dijon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mounier","sequence":"additional","affiliation":[{"name":"Hematological Malignancies Registry; Burgundy University; Dijon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roques","sequence":"additional","affiliation":[{"name":"Hematology Department; University Hospital; Dijon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Chretien","sequence":"additional","affiliation":[{"name":"Hematology Department; University Hospital; Dijon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Boulin","sequence":"additional","affiliation":[{"name":"Pharmacy Department; University Hospital; Dijon France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2015,4,10]]},"reference":[{"issue":"Suppl 5","key":"10.1111\/jcpt.12273-BIB0001|jcpt12273-cit-0001","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/annonc\/mdq201","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Baccarani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1111\/jcpt.12273-BIB0002|jcpt12273-cit-0002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1111\/jcpt.12273-BIB0003|jcpt12273-cit-0003","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12273-BIB0004|jcpt12273-cit-0004","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12273-BIB0005|jcpt12273-cit-0005","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12273-BIB0006|jcpt12273-cit-0006","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12273-BIB0007|jcpt12273-cit-0007","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jcpt.12273-BIB0008|jcpt12273-cit-0008","unstructured":"World Health Organization International classification of diseases for oncology: ICD-O 2000 http:\/\/whqlibdoc.who.int\/publications\/2000\/9241545348_eng.pdf"},{"key":"10.1111\/jcpt.12273-BIB0009|jcpt12273-cit-0009","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev4.pdf"},{"key":"10.1111\/jcpt.12273-BIB0010|jcpt12273-cit-0010","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12273-BIB0011|jcpt12273-cit-0011","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jcpt.12273-BIB0012|jcpt12273-cit-0012","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jcpt.12273-BIB0013|jcpt12273-cit-0013","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jcpt.12273-BIB0014|jcpt12273-cit-0014","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/phar.1266","article-title":"Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"33","author":"Irvine","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12273-BIB0015|jcpt12273-cit-0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12273-BIB0016|jcpt12273-cit-0016","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jcpt.12273-BIB0017|jcpt12273-cit-0017","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jcpt.12273-BIB0018|jcpt12273-cit-0018","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12273","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12273\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:53Z","timestamp":1671818753000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12273","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4,10]]}}}